{
  "document_id": "NlsPharmaceuticsLtd_20200228_F-1_EX-10.14_12029046_EX-10.14_Development Agreement",
  "file_path": "data/CUAD_v1/full_contract_pdf/Part_I/Development/NlsPharmaceuticsLtd_20200228_F-1_EX-10.14_12029046_EX-10.14_Development Agreement.pdf",
  "text_length": 67755,
  "chunk_count": 91,
  "vector_store_path": "output/vector_stores/NlsPharmaceuticsLtd_20200228_F-1_EX-10.14_12029046_EX-10.14_Development Agreement",
  "summary": "License and Development Agreement\n19. Term and Termination 18\n19.1. Term 18\n19.2. Termination for Change of Control 18\n19.3. Termination for Bankruptcy, Liquidation and similar proceedings 18\n19.4. Early Termination for Material Breach 18\n19.5. Early Termination by the Licensor 19\n19.6. Early Termination by the Licensee 19\n19.7. Consequences of Expiration or Termination 20\n20. General Provisions 20\n20.1. Amendments 20\n20.2. Notices 20\n20.3. Severability / Good Faith 20\n20.4. No Waiver 21\n20.5. No Assignment 21\n20.6. Appendices 21\n20.7. Public Announcements 21\n21. Governing Law and Jurisdiction 21\nTable of Appendices 23\nAppendix A \u2013 [Template for Licensee Reports] 24\nAppendix B \u2013 Preliminary Business Plan 25\nAppendix C*\u2013 Purpose of the JSC pre and post MA\n* No such appendix completed by the parties.\nii\nSource: NLS PHARMACEUTICS LTD., F-1, 2/28/2020\n\nLicense and Development Agreement\n(v.) the Receiving Party is required to disclose to the courts of any competent jurisdiction, or to any government regulatory\nagency, or financial authority, provided that the Receiving Party shall (i) inform the Disclosing Party as soon as is\nreasonably practicable, and (ii) at the Disclosing Party\u2019s request seek to persuade the court, agency, or authority to have\nthe information treated in a confidential manner, where this is possible under the court, agency, or authority\u2019s\nprocedures.\n18.3. Survival of Confidentiality Obligations\nThe confidentiality obligations provided in this Article shall survive any termination or expiry of this Agreement for period of ten\n(10) years.\n19. Term and Termination\n19.1. Term\nThis Agreement will come into effect on the Effective Date and shall continue in full force for ten (10) years from the Launch (the\n\nendeavour to negotiate a substitute provision that best reflects the economic intentions of the Parties without being\nunenforceable, and shall execute all agreements and documents required in this connection. The same shall apply if and to the\nextent that this Agreement is found to contain any gaps or omissions.\n20\nSource: NLS PHARMACEUTICS LTD., F-1, 2/28/2020\n\nagainst the Business Plan and propose measures to improve performance as relevant and applicable\u037e The Business Plan\nshall provide sufficient details to enable an accurate assessment of the Licensed Product performance and of the\nresources allocated by Licensee to support its commercialization.\nThe Joint Steering Committee shall meet a minimum of four times per calendar year at least once in person and otherwise by\nvideo- or telephone conference.\nThe JSC shall solely have an advisory role to the Parties.\nNotwithstanding the above, in the event of a disagreement between the Parties on pricing strategy or on any other issues\ndeemed material by one Party (the \u201cDispute\u201d), the Dispute shall be escalated to the respective CEO\u2019s of the Parties within 30 days\nfollowing its written notification by the relevant Party to the other Party.\nThe content of Licensee\u2019s public communications on NLS, including its strategies, objectives, plans, management team, board of",
  "parties": "License and Development Agreement\nIN WITNESS WHEREOF, the Parties have caused this Agreement to be duly executed in two counterparts on the date first written above, whereby\neach Party shall execute and initialize one counterpart, each of which when so executed and delivered shall be an original but shall not be effective\nuntil each Party has executed at least one counterpart, but all counterparts shall together constitute one and the same agreement.\nNLS-1 Pharma AG\n/s/ Ronald Hafner /s/ Alex Zwyer\nRonald Hafner Alex Zwyer\nChairman of the Board CEO & Member of the Board of Directors\nDate:\nEurofarma Laborat\u00f3rios S.A.\n/s/ Jul\u00edana Mazza Re\u00ees /s/ Martha Penna\nName: Jul\u00edana Mazza Re\u00ees Name: Martha Penna\ntitle: Eurofarma Laborat\u00f3rios S.A. title: Vice Pres\u00eedente Inova\u00e7\u00e4o\nD\u00edretora de Gest\u00e0o de Portf\u00f3l\u00ceo e L\u00cecen\u00e7as\nDate:\nWitnesses:\n/s/ Bruno C.Z. Baptista /s/ Walker Lahmann\nName: Bruno Castagnoli Zilli Baptista Name: Walker Lahmann\n\nagainst the Business Plan and propose measures to improve performance as relevant and applicable\u037e The Business Plan\nshall provide sufficient details to enable an accurate assessment of the Licensed Product performance and of the\nresources allocated by Licensee to support its commercialization.\nThe Joint Steering Committee shall meet a minimum of four times per calendar year at least once in person and otherwise by\nvideo- or telephone conference.\nThe JSC shall solely have an advisory role to the Parties.\nNotwithstanding the above, in the event of a disagreement between the Parties on pricing strategy or on any other issues\ndeemed material by one Party (the \u201cDispute\u201d), the Dispute shall be escalated to the respective CEO\u2019s of the Parties within 30 days\nfollowing its written notification by the relevant Party to the other Party.\nThe content of Licensee\u2019s public communications on NLS, including its strategies, objectives, plans, management team, board of\n\nafter the issuance by NLS of the corresponding invoices,\nIn the event any payment due under this Agreement is not made at the agreed term and/or for the corresponding full amount, a\nlate payment charge of ten percent (10 %) p.a. is due, calculated on a pro-rata basis of the number of days between the date at\nwhich the outstanding amount was due for payment to Licensor and the date is actually paid.\nFor the payments under Article 2.1(iii) above, referred to in Article 3.3, Licensor understands that any such payments may only\nbe remitted by Licensee after this (or a corresponding) Agreement has been recorded by the Brazilian Patent and Trademark\nOffice (\u201cINPI\u201d) and registered by the Brazilian Central Bank (\u201cBacen\u201d), as required by Brazilian law.\n4. Business Plan\nPrior to the signing of this Agreement, Eurofarma has prepared and presented to NLS a high-level business plan, focusing on the Lead\nCountries (the \u201cPreliminary Business Plan\u201d as per Appendix B ).\n\nrespective license on the terms and conditions set out in this Agreement\u037e\nD.The Parties acknowledge that further development of the Products will be necessary to develop the required Dossier as defined hereunder for\nobtaining Marketing Authorisation(s) in the Territory and wish to collaborate on the further development of the Products.\nNOW, THEREFORE, the Parties agree as follows:\n1. Definitions\nWhen used in this Agreement in capital letters, the terms and abbreviations set forth below, whether used in the singular or plural, shall\nhave the following meaning:\nAffiliates means any company, enterprise, corporation or business entity which controls, is controlled by, or is under common control\nwith, either the Licensor or Licensee. For this purpose, \u201ccontrol\u201d shall mean the possession, directly or indirectly, of the\npower to direct or cause the direction of the management and policies of an entity, whether through holding a majority of the",
  "key_terms": "License and Development Agreement\n(v.) the Receiving Party is required to disclose to the courts of any competent jurisdiction, or to any government regulatory\nagency, or financial authority, provided that the Receiving Party shall (i) inform the Disclosing Party as soon as is\nreasonably practicable, and (ii) at the Disclosing Party\u2019s request seek to persuade the court, agency, or authority to have\nthe information treated in a confidential manner, where this is possible under the court, agency, or authority\u2019s\nprocedures.\n18.3. Survival of Confidentiality Obligations\nThe confidentiality obligations provided in this Article shall survive any termination or expiry of this Agreement for period of ten\n(10) years.\n19. Term and Termination\n19.1. Term\nThis Agreement will come into effect on the Effective Date and shall continue in full force for ten (10) years from the Launch (the\n\nLicense and Development Agreement\n18. Confidentiality\n18.1. Confidentiality Obligations\na) Confidential Information shall mean any information that (i) is not publicly known (ii) has been imparted in\ncircumstances in which the recipient ought reasonably to have known that the information had been imparted in\nconfidence. This includes especially but not exclusively the information described in the clauses 18.1 b), c) and d).\nb) Each Party undertakes to maintain confidentiality as regards the execution and terms of this Agreement, and to abstain\nfrom disclosing the existence of this Agreement, its contents and all information provided to it by the other Party in\nconnection with the negotiation of this Agreement without prior written approval of the other Party.\nc) The Licensee shall maintain confidentiality with regard to the Dossier and Know-how and any operations, processes,\n\n(10) years.\n19. Term and Termination\n19.1. Term\nThis Agreement will come into effect on the Effective Date and shall continue in full force for ten (10) years from the Launch (the\n\u201cInitial Term \u201d), or the date of expiry of the last valid patent of the Licensed Product, whichever comes later, subject to clauses\n19.2, 19.3, 19.4 and 19.5 hereunder.\nBy mutual agreement of the Parties, the Initial Term may be extended by successive periods of three (3) years.\nIf any relevant registration is not successfully reached with regards to any extension of the Agreement, the Parties shall\ncooperate and negotiate on arm\u2019s length basis in order to obtain a suitable solution and achieve a proper agreement that enables\nthe Parties to fully comply with the rights, obligations and commitments herein set forth.\n19.2. Termination for Change of Control\nIn the event of a Change of Control of the Licensee, the Agreement may be terminated by Licensor with immediate effect without\n\nLicense and Development Agreement\n20.4. No Waiver\nThe failure of any of the Parties to enforce any of the provisions of this Agreement or any rights with respect thereto shall in no\nway be considered as a waiver of such provisions or rights or in any way affect the validity of this Agreement.\n20.5. No Assignment\nThis Agreement may not be assigned or otherwise transferred, nor may any right or obligations hereunder be assigned or\ntransferred, by either Party without the prior written consent of the other Party\u037e provided, however, that Licensor may, without\nsuch consent, assign this Agreement and its rights and obligations hereunder, in whole or in part, to an Affiliate or in connection\nwith the transfer or sale of all or substantially all of its assets related to the Licensed Product or the business relating thereto, or\nin the event of its merger or consolidation or change in control or similar transaction. Licensor shall however refrain from any"
}